ARMC1 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population derived from the human A-549 lung adenocarcinoma line, with targeted disruption of the ARMC1 gene. This heterogeneous pool contains diverse loss-of-function mutations, offering a robust model for studying ARMC1-dependent mitochondrial regulation while avoiding clonal artifacts. CRISPR/Cas9-mediated gene disruption ensures stable ablation of ARMC1, enabling reproducible analysis of mitochondrial fission, ubiquitin-proteasome signaling, and apoptosis in a lung cancer context. As polyclonal knockout cells, they maintain genetic diversity while eliminating target gene function, making them ideal for population-level studies of mitochondrial dynamics and drug response.
The parental A-549 cell line originated from the lung adenocarcinoma of a 58-year-old Caucasian male and serves as a model of alveolar Type II epithelial cells. These adherent, hypotriploid cells retain key lung adenocarcinoma features, including oncogenic mutations and metabolic alterations, and are widely used in lung cancer research. They recapitulate uncontrolled proliferation, apoptosis resistance, and metabolic reprogramming, with well-characterized signaling networks. Their epithelial origin makes them a suitable platform for examining mitochondrial function in non-small cell lung cancer and related pathologies.
ARMC1 acts as an adaptor for the E3 ubiquitin ligase MARCH5, facilitating interaction with mitochondrial fission/fusion effectors such as DRP1, MFF, FIS1, MIEF1, MFN1, and MFN2. Through modulation of MARCH5-mediated ubiquitination, ARMC1 controls turnover and activity of these proteins, regulating DRP1-dependent mitochondrial fission. Activated by mitochondrial membrane depolarization and ER-mitochondria contact site signals, this axis influences mitochondrial morphology and apoptotic sensitivity. ARMC1-MARCH5 thus serves as a critical mitochondrial quality-control checkpoint. Knockout of ARMC1 disrupts ubiquitin-proteasomal regulation of its targets, leading to altered mitochondrial architecture and apoptosis resistance, a phenotype relevant in cancer cells.
In A-549 cells, ARMC1 knockout enables dissection of mitochondrial contributions to lung adenocarcinoma progression. Lung cancer cells frequently display altered mitochondrial dynamics and apoptosis resistance; ARMC1??s role in quality control may modulate these traits. Eliminating ARMC1 in this polyclonal background allows investigation of how fission perturbations affect tumor survival, metabolic adaptation, and chemotherapeutic response. The model correlates mitochondrial morphology changes with drug sensitivity, offering insights into therapy resistance mechanisms. Additionally, ARMC1-MARCH5-DRP1 interactions can be explored in lung-cancer-specific signaling contexts, providing a relevant system for preclinical studies.
Key applications include high-content immunofluorescence imaging of mitochondrial morphology, western blot analysis of DRP1, p-DRP1, MFF, MARCH5, and ARMC1, and flow cytometry for apoptosis and mitochondrial membrane potential. Co-immunoprecipitation and ubiquitination assays can probe MARCH5-ARMC1 interactions, while MTS/MTT viability assays evaluate drug sensitivity. These cells are ideal for studying mitochondrial dynamics in lung adenocarcinoma, apoptosis resistance mechanisms, and screening MARCH5-ARMC1 pathway modulators. For further information or custom requests, please contact Ascent Research.
